GlycoMimetics (GLYC) Reports Encouraging Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients
Tweet Send to a Friend
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that of the first 13 evaluable patients in its clinical trial of GMI-1271 in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
